Study: Intensive ranibizumab treatment boosts DME outcomes

10/15/2012 | Medscape (free registration)

Intensive therapy with ranibizumab, a monoclonal antibody that inhibits vascular endothelial growth factor, fared better than laser therapy alone or laser therapy plus ranibizumab in improving best-corrected visual acuity and foveal thickness in diabetic macular edema patients between 24 and 36 months, a study indicated. The findings in the Archives of Ophthalmology demonstrate that using anti-VEGF agents is safe and effective for treating DME, researchers noted.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC